Naoki Yoshimoto

537 total citations
33 papers, 384 citations indexed

About

Naoki Yoshimoto is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Naoki Yoshimoto has authored 33 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Naoki Yoshimoto's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (10 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Naoki Yoshimoto is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (10 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Naoki Yoshimoto collaborates with scholars based in Japan and United States. Naoki Yoshimoto's co-authors include Tomoya Kawaguchi, Shigeki Mitsuoka, Tatsuo Kimura, Kazuto Hirata, Tomohiro Suzumura, Kazuhisa Asai, Toshiyuki Nakai, Yasuhiro Koh, Naruo Yoshimura and Tetsuya Watanabe and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and Cancer.

In The Last Decade

Naoki Yoshimoto

32 papers receiving 380 citations

Peers

Countries citing papers authored by Naoki Yoshimoto

Since Specialization

Citations

This map shows the geographic impact of Naoki Yoshimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Yoshimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Yoshimoto more than expected).

Fields of papers citing papers by Naoki Yoshimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Yoshimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Yoshimoto. The network helps show where Naoki Yoshimoto may publish in the future.

Co-authorship network of co-authors of Naoki Yoshimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Naoki Yoshimoto. A scholar is included among the top collaborators of Naoki Yoshimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoki Yoshimoto. Naoki Yoshimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer 2024 ·Scientific Reports ·Akira Sugimoto, Hiroyasu Kaneda, Naoki Yoshimoto, Kenji Nagata, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Haruo Inokuchi, Keiko Shibuya, (unknown), (unknown), Kenji Nakahama, (unknown), (unknown), (unknown), (unknown)	2
2	Vimentin expression correlates with immune checkpoint inhibitor efficacy in non–small cell lung cancer 2023 ·Cancer ·Kenji Nakahama, (unknown), Naoki Yoshimoto, Mitsuru Fukui, Akira Sugimoto, (unknown), K. Ogawa, Kenji Sawa, (unknown), Hiroyasu Kaneda, Shigeki Mitsuoka, Tetsuya Watanabe, Kazuhisa Asai, Tomoya Kawaguchi	2
3	Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer 2023 ·Cancer Chemotherapy and Pharmacology ·Kenji Nakahama, (unknown), Naoki Yoshimoto, Mitsuru Fukui, Akira Sugimoto, (unknown), (unknown), Kenji Sawa, (unknown), Hiroyasu Kaneda, Shigeki Mitsuoka, (unknown), Kazuhisa Asai, Tomoya Kawaguchi	4
4	RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression 2023 ·Anticancer Research ·(unknown), Masakazu Yashiro, Naoki Yoshimoto, (unknown), Akira Sugimoto, Kenji Nakahama, (unknown), (unknown), Kenji Sawa, (unknown), Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhiro Yamada, (unknown), (unknown), (unknown), Akila Mayeda, Tomoya Kawaguchi	3
5	A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia 2022 ·Respiratory Medicine Case Reports ·(unknown), Hiroyuki Matsuura, Yusuke Sakurai, (unknown), (unknown), Naoki Yoshimoto, (unknown), Fumio Yamasaki, (unknown), Tomonori Hirashima	2
6	The Impact of Estrogen Receptor Expression on Mutational Status in the Evolution of Non-Small Cell Lung Cancer 2022 ·Clinical Lung Cancer ·(unknown), Hiroyasu Kaneda, Yasuhiro Koh, Akihiro Tamiya, Shun‐ichi Isa, Akihito Kubo, (unknown), (unknown), Kenji Sawa, Naoki Yoshimoto, Shigeki Mitsuoka, Tomoya Kawaguchi	2
7	Association of thyroid transcription factor‐1 with the efficacy of immune‐checkpoint inhibitors in patients with advanced lung adenocarcinoma 2022 ·Thoracic Cancer ·Kenji Nakahama, Hiroyasu Kaneda, (unknown), (unknown), Naoki Yoshimoto, Akira Sugimoto, (unknown), (unknown), (unknown), Kenji Sawa, (unknown), Shigeki Mitsuoka, Tetsuya Watanabe, Kazuhisa Asai, Tomoya Kawaguchi	13
8	SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3 2022 ·Translational Lung Cancer Research ·Kenji Nakahama, (unknown), (unknown), Naoki Yoshimoto, Akira Sugimoto, (unknown), (unknown), (unknown), Kenji Sawa, (unknown), Hiroyasu Kaneda, Shigeki Mitsuoka, Tetsuya Watanabe, Kazuhisa Asai, Tomoya Kawaguchi	1
9	Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer 2022 ·BMC Cancer ·(unknown), Tomoya Kawaguchi, Masaru Watanabe, Shun‐ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Chiyoe Kitagawa, Naoki Yoshimoto, Yasuhiro Koh	1
10	Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan 2020 ·BMJ Open ·(unknown), Yasuhiro Koh, Hiroyasu Kaneda, (unknown), (unknown), Kenji Sawa, Mitsuru Fukui, Yoshihiko Taniguchi, Naoki Yoshimoto, Akihiro Tamiya, Masahiko Ando, Akihito Kubo, Shun‐ichi Isa, Hideo Saka, Akihide Matsumura, Tomoya Kawaguchi	6
11	A Case of Dapsone-induced Mild Methemoglobinemia with Dyspnea and Cyanosis. 2020 ·PubMed ·(unknown), Hisayoshi Imanishi, Naoki Yoshimoto, (unknown), (unknown)	1
12	Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 2019 ·Lung Cancer ·(unknown), Kenji Sawa, Mitsuru Fukui, Jun Oyanagi, Naoki Yoshimoto, Tomohiro Suzumura, Tetsuya Watanabe, Hiroyasu Kaneda, Shigeki Mitsuoka, Kazuhisa Asai, Tatsuo Kimura, Nobuyuki Yamamoto, Kazuto Hirata, Yasuhiro Koh, Tomoya Kawaguchi	9
13	Efficacy and safety of ultrasound (US) guided percutaneous needle biopsy for peripheral lung or pleural lesion: comparison with computed tomography (CT) guided needle biopsy 2019 ·Journal of Thoracic Disease ·Norio Yamamoto, Tetsuya Watanabe, Kazuhiro Yamada, Toshiyuki Nakai, Tomohiro Suzumura, (unknown), Naoki Yoshimoto, Kanako Sato, Hidenori Tanaka, Shigeki Mitsuoka, (unknown), Tatsuo Kimura, Hiroshi Kanazawa, Kazuto Hirata, Tomoya Kawaguchi	46
14	Abstract 2613: Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 2018 ·Cancer Research ·(unknown), Kenji Sawa, Jun Oyanagi, Mitsuru Fukui, Naoki Yoshimoto, Tomohiro Suzumura, Shigeki Mitsuoka, Kazuhisa Asai, Tatsuo Kimura, Nobuyuki Yamamoto, Tomoya Kawaguchi, Kazuto Hirata, Yasuhiro Koh	1
15	PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort 2017 ·Lung Cancer ·Kenji Sawa, Yasuhiro Koh, Tomoya Kawaguchi, (unknown), Kazuhisa Asai, Shigeki Mitsuoka, Tatsuo Kimura, Naruo Yoshimura, Naoki Yoshimoto, Akihito Kubo, Hideo Saka, Akihide Matsumura, Hideki Wanibuchi, Nobuyuki Yamamoto, Noritoshi Nishiyama, Kazuto Hirata	19
16	Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR 2016 ·Expert Opinion on Pharmacotherapy ·Shigeki Mitsuoka, Tomoya Kawaguchi, Akihito Kubo, Shun‐ichi Isa, Kazuhisa Asai, (unknown), Tetsuya Watanabe, Kenji Sawa, Naoki Yoshimoto, (unknown), Toshiyuki Nakai, Tomohiro Suzumura, Hidenori Tanaka, (unknown), Tatsuo Kimura, Naruo Yoshimura, Shinzoh Kudoh, Kazuto Hirata	2
17	Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats 2015 ·Neuropharmacology ·(unknown), (unknown), Yuji Kawahara, Noriko Morimoto, (unknown), Masashi Kato, Yoshiyuki Yamaura, Naoki Yoshimoto, Hideaki Suna, Seishi Katsumata	18
18	Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation 2015 ·Lung Cancer ·Naruo Yoshimura, Shinzoh Kudoh, Shigeki Mitsuoka, Naoki Yoshimoto, (unknown), Toshiyuki Nakai, (unknown), (unknown), Yoshihiro Tochino, Kazuhisa Asai, Tatsuo Kimura, Tomoya Kawaguchi, Kazuto Hirata	42
19	Crucial role of impaired Kupffer cell phagocytosis on the decreased Sonazoid‐enhanced echogenicity in a liver of a nonalchoholic steatohepatitis rat model 2010 ·Hepatology Research ·(unknown), Hiroko Iijima, Masaki Saito, Hironori Tanaka, Hiroyasu Imanishi, Naoki Yoshimoto, Tomohiro Yoshimoto, Shizue Futatsugi‐Yumikura, Kenji Nakanishi, Tohru Tsujimura, Takashi Nishigami, Atsushi Kudo, Shigeki Arii, Shuhei Nishiguchi	20
20	SLOWED VENTRICULAR UNTWISTING IS RELATED TO DECREASED ELASTIC RECOIL BUT NOT TO INCREASED MYOCARDIAL FIBROSIS IN HYPERTROPHIC CARDIOMYOPATHY 2010 ·Journal of the American College of Cardiology ·(unknown), Akiko Goda, (unknown), (unknown), Mika Matsumoto, (unknown), Akiyo Eguchi, (unknown), Naoki Yoshimoto, Masaaki Lee‐Kawabata, Takeshi Tsujino, Tohru Masuyama	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomohiro Suzumura Breakdown of academic impact, for papers by Peipei Shi Breakdown of academic impact, for papers by Kang Wang Breakdown of academic impact, for papers by Georgios Tsakonas Breakdown of academic impact, for papers by Kouki Ohtsuka Breakdown of academic impact, for papers by Antonio Vavallo Breakdown of academic impact, for papers by Georgios Kesisis Breakdown of academic impact, for papers by Juan Zhou